Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | The future of the UV1 vaccine program in ovarian cancer

Trine Nøttrup, PhD, Rigshospitalet, Copenhagen, Denmark, comments on the challenges of continuing the UV1 vaccine program in ovarian cancer, but expresses enthusiasm for further translational research to characterize patients who responded to the vaccine. The availability of tissue and blood samples for future studies means that there is potential for collaboration with other companies to explore the role of immunotherapeutic therapy in ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Unfortunately, the company behind the vaccine has closed the program. It’s been adopted by another company and we cannot go further with this particular vaccine. But we really do want to move further and to find out and classify more specifically what characterizes these patients who did have a response. And we do have lots of tissue and blood to work further on with translational research, which is going to be our next step...

Unfortunately, the company behind the vaccine has closed the program. It’s been adopted by another company and we cannot go further with this particular vaccine. But we really do want to move further and to find out and classify more specifically what characterizes these patients who did have a response. And we do have lots of tissue and blood to work further on with translational research, which is going to be our next step. And we are looking out for other companies who will be willing to work with us to further elaborate if there are a place in this landscape of immunotherapeutic therapy for ovarian cancer, which we know there will be, we just have to find the right patients to do it for. So we will be looking out for collaboration with companies in the future as well.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.